NCI has issued a Request for Information seeking input from developers of multi-cancer early detection liquid biopsy tests, with the goal of launching an NCI-sponsored randomized controlled screening clinical trial of these tools.
Racial and ethnic inequities are pervasive in clinical research—from the systemic factors that deter underrepresented populations from pursuing careers in science and medicine, to the discrimination, lack of support, and other hardships faced by those who do enter the biomedical profession.
Julie E. Bauman was named director of the George Washington University Cancer Center. She will also serve as professor of medicine in the GW School of Medicine and Health Sciences.
An anonymous donor has made a $25 million gift to UNC Lineberger Comprehensive Cancer Center to establish the UNC Lineberger Center for Triple Negative Breast Cancer and to support other UNC Lineberger research initiatives.
Faith E. Davies was named the inaugural director of the Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.
The University of Colorado Cancer Center has announced several leadership changes:
Amy Jo Jenkins was named associate director of administration for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. Succeeding Jenkins, Matthew Kovak was promoted to executive director of the clinical trials office.
Wendy Stock and Geoffrey Uy were named co-chairs of the Leukemia Committee of the Alliance for Clinical Trials in Oncology.
Anat Kendal was named Chief Financial Officer of the Pancreatic Cancer Action Network. Kendal, whose appointment is effective immediately, reports to Julie Fleshman, president and CEO of PanCAN.
UNC Lineberger Comprehensive Cancer Center researchers demonstrated that a novel combination of Pfizer’s Ibrance (palbociclib) and Millennium Pharmaceuticals’ sapanisertib, delivered in a nanoparticle formulation, extended the survival of mice with medulloblastoma.
